Free Trial
NASDAQ:CTMX

CytomX Therapeutics (CTMX) Stock Price, News & Analysis

CytomX Therapeutics logo
$2.49 +0.01 (+0.40%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$2.49 0.00 (0.00%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CytomX Therapeutics Stock (NASDAQ:CTMX)

Key Stats

Today's Range
$2.44
$2.52
50-Day Range
$0.65
$2.99
52-Week Range
$0.40
$3.10
Volume
755,783 shs
Average Volume
2.19 million shs
Market Capitalization
$200.74 million
P/E Ratio
5.19
Dividend Yield
N/A
Price Target
$5.33
Consensus Rating
Buy

Company Overview

CytomX Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

CTMX MarketRank™: 

CytomX Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 460th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CytomX Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CytomX Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about CytomX Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.05) to ($0.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CytomX Therapeutics is 5.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.56.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CytomX Therapeutics is 5.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.60.

  • Read more about CytomX Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    27.61% of the float of CytomX Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytomX Therapeutics has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in CytomX Therapeutics has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CytomX Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CytomX Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    27.61% of the float of CytomX Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytomX Therapeutics has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in CytomX Therapeutics has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CytomX Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 13 people have searched for CTMX on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.60% of the stock of CytomX Therapeutics is held by insiders.

  • Percentage Held by Institutions

    67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about CytomX Therapeutics' insider trading history.
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Stock News Headlines

CytomX Therapeutics, Inc. (CTMX) - Yahoo Finance
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

CTMX Stock Analysis - Frequently Asked Questions

CytomX Therapeutics' stock was trading at $1.03 at the start of the year. Since then, CTMX stock has increased by 141.7% and is now trading at $2.49.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its quarterly earnings data on Monday, May, 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. The biotechnology company earned $50.92 million during the quarter, compared to the consensus estimate of $35.42 million. CytomX Therapeutics had a negative trailing twelve-month return on equity of 553.71% and a net margin of 28.22%.
Read the conference call transcript
.

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), CymaBay Therapeutics (CBAY), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/12/2025
Today
7/04/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CTMX
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.33
High Stock Price Target
$6.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+114.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
5.19
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$31.87 million
Pretax Margin
28.35%

Debt

Sales & Book Value

Annual Sales
$138.10 million
Cash Flow
$0.36 per share
Price / Cash Flow
6.85
Book Value
($0.01) per share
Price / Book
-249.00

Miscellaneous

Free Float
75,300,000
Market Cap
$200.74 million
Optionable
Optionable
Beta
2.05

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:CTMX) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners